Belite Bio, Inc BLTE
Set alert
154.74 USD +4.46 +2.97%
At close · Oct 30
154.74 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
146.90 Day range 156.33
98.10 52-week range 193.61
- YTD
- -3.26%
- 1 year
- +57.74%
- Open
- 148.79
- Prev close
- 150.28
- Mkt cap
- 6.23B
- Vol
- 234.88K
- Avg vol
- 177.42K
- EPS
- -2.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 146.90
- High
- 156.33
- Forward P/E
- 68.52
- Beta
- -1.23
- Short ratio
- 7.77
- Inst. own
- 24.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 161.62
- 200-d avg
- 160.36
- 1y target
- 228.89
5Y chart
Events in this range
- Aug 11, 2025Earnings: -0.5; estimate -0.47; surprise -6.38%
- Nov 10, 2025Earnings: -0.65; estimate -0.53; surprise -22.64%
- Mar 2, 2026Earnings: -0.38; estimate -0.56; surprise 32.14%
- May 20, 2026Earnings: -0.34; estimate -0.6; surprise 43.33%
- Aug 12, 2026Earnings: -0.7; estimate -0.73; surprise 4.11%
- Aug 14, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 14, 2026Rating: Morgan Stanley · Overweight → Overweight
- Sep 4, 2026Rating: Canaccord Genuity · — → Buy
- Sep 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 9, 2026Rating: Mizuho · Outperform → Outperform
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (91)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bearish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 6 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| MACD: Buy Signal | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 20, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Nov 25, 2024 | 1 year ago |
| RSI: Overbought | Oct 21, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 7, 2024 | 2 years ago |
| SMA: Bullish | Sep 30, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| MACD: Buy Signal | May 27, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Mar 25, 2024 | 2 years ago |
| SMA: Bullish | Mar 18, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 19, 2024 | 2 years ago |
| RSI: Overbought | Feb 5, 2024 | 2 years ago |
| RSI: Overbought | Nov 27, 2023 | 2 years ago |
| RSI: Overbought | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 17, 2023 | 3 years ago |
| RSI: Oversold | May 29, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 13, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 13, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Nov 21, 2022 | 3 years ago |
| SMA: Bullish | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Oct 3, 2022 | 4 years ago |
| SMA: Bullish | Aug 29, 2022 | 4 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
Key statistics
- Market cap
- 6.24B
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 68.52
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.03
- EPS (TTM)
- -2.74
- Beta
- -1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.10%
- Shares outstanding
- 40.27M
- Short % of float
- 6.03%
- 50-day average
- 161.62
- 200-day average
- 160.36
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 228.89 +47.9% upside
Now 154.74
- Target (low)
- 185.00
- Target (mean)
- 228.89
- Target (high)
- 303.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.76875.
Financials — quick view
BLTE Revenue — quarterly 0
BLTE Net income — quarterly -25.32M
BLTE EPS — quarterly -0.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.78627 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.73 | -0.70 | +0.03 | +4.11% |
| May 20, 2026 | Mar 31, 2026 | -0.60 | -0.34 | +0.26 | +43.33% |
| Mar 2, 2026 | Dec 31, 2025 | -0.56 | -0.38 | +0.18 | +32.14% |
| Nov 10, 2025 | Sep 30, 2025 | -0.53 | -0.65 | -0.12 | -22.64% |
| Aug 11, 2025 | Jun 30, 2025 | -0.47 | -0.50 | -0.03 | -6.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 9, 2026 | Mizuho | main | Outperform | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 4, 2026 | Canaccord Genuity | init | — | Buy |
| Aug 14, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 14, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- belitebio.com
News
- Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19
- Belite Bio Announces Uplisting to the Nasdaq Global Select Market
- Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1
- Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
- Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
- Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
- Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC
- Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
- Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Your note
Sign in to keep a note on BLTE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN WAN-SHAN | Director | Sale | Apr 8, 2026 | 9,096 |
| CHUANG HAO-YUAN | Chief Financial Officer | Sale | Sep 7, 2026 | 26,038 |
| LIN YU-HSIN | Chief Executive Officer | Sale | Sep 7, 2026 | 70,134 |
| MATA NATHAN L. | Officer | Sale | May 6, 2026 | 0 |
| SCHOLL HENDRIK PETER | Officer | Sale | Sep 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 7.64% | 3,077,219 | 476.51M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 3.06% | 1,232,877 | 190.91M | Jun 29, 2026 |
| RTW Investments LP | 1.78% | 715,332 | 110.77M | Jun 29, 2026 |
| Millennium Management Llc | 1.23% | 494,564 | 76.58M | Jun 29, 2026 |
| Maverick Capital Ltd. | 0.98% | 396,311 | 61.37M | Jun 29, 2026 |
| Eventide Asset Management LLC | 0.97% | 390,829 | 60.52M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.97% | 390,829 | 60.52M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.20% | 80,462 | 12.46M | Jun 29, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF | 0.07% | 30,052 | 4.65M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 6,727 | 1.04M | Aug 30, 2026 |
| T. ROWE PRICE Eqy. SERIES, INC.-T. Rowe Price Health Sciences PORT. | 0.01% | 5,400 | 836.19K | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity ZERO International Index Fund | 0.01% | 5,934 | 918.88K | Aug 30, 2026 |